
	Application Number:	10/074,596
	Filing Date:	February 12, 2002
	First Named Inventor:	Michael G. Rosenblum
	Art Unit:	1614
	Examiner Name:	Unknown
Total Number of Pages in this Submission : _____		Attorney Docket Number: CLFR:007US

## ENCLOSURES (check all that apply)


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input checked="" type="checkbox"/> Form PTO-1449 <input checked="" type="checkbox"/> References A1-A43, B1-B41, C1-C145 <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 <input type="checkbox"/> Declaration(s) _____ <input type="checkbox"/> Copy of Notice of Missing Parts	<input type="checkbox"/> Drawings(s) _____ <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Statement under 37 CFR §3.73(b) <input type="checkbox"/> Designation of Patent Practitioners <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below) <input type="checkbox"/> Check in the amount of \$ <input checked="" type="checkbox"/> Authorized to be charged to deposit account if check insufficient or inadvertently omitted Deposit account number: <u>50-1212/CLRF:007US</u> <input type="checkbox"/> Sequence Statement <input type="checkbox"/> Paper Copy of Sequence Listing <input type="checkbox"/> Computer Readable Form (CRF) <input checked="" type="checkbox"/> Postcard <input type="checkbox"/> _____ <input type="checkbox"/> _____
--	---	--

Remarks:

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Fulbright & Jaworski, L.L.P.	Customer Number	32425
Signature			
Printed Name	David L. Parker	Reg. No.	32,165
Date	May 26, 2005		

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: MS AMENDMENT Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or Printed Name	David L. Parker	Date	May 26, 2005

**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Michael G. Rosenblum

Lawrence Cheung

Serial No.: 10/074,596

Filed: February 12, 2002


For: MODIFIED PROTEINS, DESIGNER  
TOXINS, AND METHODS OF MAKING  
THEREOF



Group Art Unit: 1614

Examiner: Unknown

Atty. Dkt. No.: CLFR:007US

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
May 26, 2005	
Date	David L. Parker

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**MS AMENDMENT**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/CLFR:007US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,  


David L. Parker  
Reg. No. 32,165  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: May 26, 2005

Form PTO-1449 (modified)

Atty. Docket No.  
CLFR:007USSerial No.  
10/074,596

List of Patents and Publications for Applicant's

Applicant  
Michael Rosenblum et al.

INFORMATION DISCLOSURE STATEMENT

Filing Date:  
February 12, 2002Group:  
1614

(Use several sheets if necessary)

U.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 3Other Art  
See Page 4

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A7	2004/0009477	1/15/04	Fernandez <i>et al.</i>	435	6	11/21/01
	A8	2004/0013691	1/22/04	Rosenblum	424	234.1	6/12/03
	A9	4,263,279	4/21/81	Sela <i>et al.</i>	424	85	7/24/78
	A10	4,414,148	11/8/83	Jansen <i>et al.</i>	530	391.9	4/14/82
	A11	4,522,918	6/11/85	Schlom <i>et al.</i>	435	68	12/15/81
	A12	4,590,071	5/20/86	Scannon <i>et al.</i>	424	85	11/25/84
	A13	4,650,674	3/17/87	Aggarwal <i>et al.</i>	424	85	12/3/84
	A14	4,671,958	6/9/87	Rodwell <i>et al.</i>	424	85	3/9/82
	A15	4,677,064	6/30/87	Mark <i>et al.</i>	435	68	5/2/85
	A16	4,753,894	6/28/88	Frankel <i>et al.</i>	436	548	1/11/85
	A17	4,771,128	11/13/88	Ferris <i>et al.</i>	530	391.7	10/10/86
	A18	4,801,578	6/4/84	Monsigny <i>et al.</i>	514	8	6/4/84
	A19	4,831,122	5/16/89	Buchsbaum <i>et al.</i>	530	391.3	1/9/86
	A20	4,863,726	11/5/89	Stevens <i>et al.</i>	424	85.2	12/9/87
	A21	4,870,163	11/26/89	Rubin <i>et al.</i>	530	413	8/29/85
	A22	4,888,415	12/19/89	Lambert <i>et al.</i>	530	390	3/7/88
	A23	4,894,225	1/16/90	Zimmerman	424	85.1	3/2/87
	A24	4,894,227	1/16/90	Stevens <i>et al.</i>	424	85.2	5/29/87
	A25	4,894,443	1/16/90	Greenfield <i>et al.</i>	530	388	11/7/84
	A26	4,935,233	6/19/90	Bell <i>et al.</i>	424	85.5	12/2/85
	A27	4,946,778	8/7/90	Landner <i>et al.</i>	435	69.6	1/19/89
	A28	4,963,354	10/16/90	Shepard <i>et al.</i>	424	85.1	1/21/87
	A29	4,980,457	12/25/90	Jansen <i>et al.</i>	530	391	11/11/87

25527784.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)		Atty. Docket No. CLFR:007US	Serial No. 10/074,596
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Michael Rosenblum et al.	
		Filing Date: February 12, 2002	Group: 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 3</i>	Other Art <i>See Page 4</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A30	5,017,371	5/21/91	Cummins	424	85.6	1/6/88
	A31	5,019,368	5/28/91	Epstein <i>et al.</i>	424	1.1	2/23/89
	A32	5,032,521	7/16/91	White <i>et al.</i>	435	240.27	3/23/87
	A33	5,134,075	7/28/92	Hellstrom et al.	530	387.3	2/17/89
	A34	5,624,827	4/29/97	Rosenblum and Beattie	435	91.5	10/21/94
	A35	5,720,954	2/24/98	Hudziak <i>et al.</i>	424	130.1	5/23/95
	A36	5,744,580	4/28/98	Better <i>et al.</i>	530	377	6/7/95
	A37	5,770,195	6/23/98	Hudziak <i>et al.</i>	424	130.1	5/23/95
	A38	6,214,974	4/10/01	Rosenblum and Donato	530	391.9	3/27/95
	A39	6,306,626	10/23/01	Rosenblum and Donato	435	70.21	2/07/94
	A40	6,599,505	7/29/03	Rosenblum	424	134.1	2/19/98
	A41	6,669,938	12/30/03	Rosenblum <i>et al.</i>	424	183.1	11/24/93
	A42	6,750,329	6/15/04	Rosenblum <i>et al.</i>	530	391.7	5/31/94
	A43	RE37,642	12/04/01	Rosenblum <i>et al.</i>	530	370	5/20/99
	A44	10/676,725		Rosenblum			10/01/03
	A45	10/926,731		Rosenblum			8/26/04
	A46	2003/0073163	4/17/03	Fernandez <i>et al.</i>	435	69.1	11/14/01
	A47	2003/0086919	5/08/03	Rosenblum and Liu	424	94.63	7/17/02
	A48	2003/0134302	7/17/03	Fernandez <i>et al.</i>	435	6	8/01/02
	A49	2003/0186384	10/02/03	Barth <i>et al.</i>	435	69.5	4/20/01

25527784.1

**EXAMINER:****DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

*INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)*

Form PTO-1449 (modified)		Atty. Docket No. CLFR:007US	Serial No. 10/074,596
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Michael Rosenblum et al.	
		Filing Date: February 12, 2002	Group: 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 3</i>	Other Art <i>See Page 4</i>	

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B2	AU A21725/88	3/23/89	Australia			English
	B3	AU A30753/89	8/31/89	Australia			English
	B4	AU B79527/87	4/14/88	Australia			English
	B5	AU B82047/87	6/9/88	Australia			English
	B6	EP 0118365	3/2/84	Europe			English
	B7	EP 0150126	7/31/85	Europe			English
	B8	EP 0160446	4/15/85	Europe			English
	B9	EP 0184369	11/26/85	Europe			English
	B10	EP 0222360	5/20/87	Europe			English
	B11	EP 0226418	12/5/86	Europe			English
	B12	EP 0256714	2/24/88	Europe			English
	B13	EP 0281070	9/7/88	Europe			English
	B14	EP 0305967	3/8/89	Europe			None
	B15	EP 0336631	10/11/89	Eurpoe			English
	B16	EP 0350230	1/10/90	Europe			English
	B17	EP 0396387	11/7/90	Europe			English
	B18	GB 1564666	1/27/78	United Kingdom			English
	B19	GB 2148299	5/30/85	United Kingdom			English
	B20	JP 190200	8/20/87	Japan			Partial
	B21	JP 62209098	12/6/86	Japan			Abstract
	B22	JP 86121	7/13/81	Japan			Partial
	B23	WO 85/00974	8/31/84	WIPO			English
	B24	WO 86/02945	5/22/86	WIPO			English

25527784.1

**EXAMINER:****DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:007US	Serial No. 10/074,596
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Michael Rosenblum et al.	
		Filing Date: February 12, 2002	Group: 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 3</i>	Other Art <i>See Page 4</i>	

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B25	WO 86/05098	7/8/85	WIPO			English
	B26	WO 87/00056	6/6/86	WIPO			English
	B27	WO 88/09343	12/1/88	WIPO			Abstract
	B28	WO 88/09344	12/1/88	WIPO			English
	B29	WO 89/06692	7/27/89	WIPO			English
	B30	WO 90/00405	1/25/90	WIPO			English
	B31	WO 91/16071	10/31/91	WIPO			English
	B32	WO 94/26910	11/24/94	WIPO			English
	B33	WO 97/22364	6/26/97	WIPO			English
	B34	WO 97/46259	12/11/97	WIPO			English
	B35	WO 99/49059	9/30/99	WIPO			English
	B36	WO 99/40198	8/12/99	WIPO			English
	B37	WO 99/45128	9/10/99	WIPO			English
	B38	WO 99/51620	10/14/99	WIPO			English
	B39	WO 99/51766	10/14/99	WIPO			English
	B40	WO 03/002598	1/09/03	WIPO			English
	B41	WO 00/34317	6/15/00	WIPO			English
	B42	AU A13017/88	9/15/88	Australia			English

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C40	Gase <i>et al.</i> , "Functional significance of NH <sub>2</sub> - and COOH- terminal regions of staphylokinase in plasminogen activation," <i>Thrombosis and Haemostasis</i> , 76(5):755-760, 1996.

25527784.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:007US	Serial No. 10/074,596
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Michael Rosenblum et al.	
		Filing Date: February 12, 2002	Group: 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 3</i>	Other Art <i>See Page 4</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C41	Giacomini <i>et al.</i> , "Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells," <i>J. Immunol.</i> , 133(3):1649-1655, 1984.
	C42	Gillies <i>et al.</i> , "Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities," <i>Hum. Antibodies Hybridomas.</i> , 1:47-54, 1990.
	C43	Gould <i>et al.</i> , "Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies," <i>J. Natl. Cancer Inst.</i> , 81:775-781, 1989.
	C44	Green <i>et al.</i> , "Monoclonal antibody therapy for solid tumors," <i>Cancer Treat Rev.</i> , 26:269-286, 2000.
	C45	Greiner <i>et al.</i> , "Differential effects of recombinant human leukocyte interferons on cell surface antigen expression," <i>Cancer Res.</i> , 46:4984-4990, 1986.
	C46	Greiner <i>et al.</i> , "Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment," <i>Cancer Res.</i> , 44:3208-3214, 1984.
	C47	Haddad <i>et al.</i> , "Structural organization of the hCTLA-1 gene encoding human granzyme B," <i>Gene</i> , 87(2):265-271, 1990.
	C48	Hamburger and Salmon, "Primary bioassay of human tumor stem cells," <i>Science</i> , 197:461-463, 1977.
	C49	Hann <i>et al.</i> , "Building 'validated' mouse models of human cancer," <i>Curr. Opin. Cell Biol.</i> , 13:778-784, 2001.
	C50	Hanson <i>et al.</i> , "A cluster of hematopoietic serine protease genes is found on the same chromosomal band as the human $\alpha/\delta$ T-cell receptor locus," <i>Proc. Natl. Acad. Sci., USA</i> , 87:960-963, 1990.
	C51	Harlow <i>et al.</i> , <i>Antibodies: A laboratory Manual</i> , Cold Spring Harbor Press, pp. 72-77, 92-97, 128-135, and 141-157, 1988.
	C52	Harper <i>et al.</i> , "Proximity of the CTLA-1 serine esterase and Tcr alpha loci in mouse and man," <i>Immunogenetics</i> , 28(6):439-444, 1988.

25527784.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)		Atty. Docket No. CLFR:007US	Serial No. 10/074,596
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Michael Rosenblum et al.	
		Filing Date: February 12, 2002	Group: 1614
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 3	Other Art See Page 4	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C53	Henkart, "Mechanism of Lymphocyte-mediated Cytotoxicity," <i>Ann. Rev. Immunol.</i> , 3:31-58, 1985.
	C54	Hertler <i>et al.</i> , "A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia," <i>J. Biol. Response Mod.</i> , 7:97-113, 1987.
	C55	Hoogenboom <i>et al.</i> , "Targeting of tumor necrosis factor to tumor cells: secretion by myeloma cells of a genetically engineered antibody-tumor necrosis factor hybrid molecule," <i>Biochim Biophys Acta.</i> , 1096:345-354, 1991.
	C56	Huston <i>et al.</i> , "Single-chain immunotechnology of Fv analogues and fusion proteins," in <i>Immunotechnology</i> , Gosling and Reen (eds), pg. 47-60, 1993.
	C57	Imai <i>et al.</i> , "[Current status of monoclonal antibodies to human melanoma and its application]," <i>Gan To Kagaku Ryoho.</i> , 10:852-860, 1983 (abstract in English).
	C58	Imai <i>et al.</i> , "Differential effect of interferon on the expression of tumor-associated antigens and histocompatibility antigens on human melanoma cells: relationship to susceptibility to immune lysis mediated by monoclonal antibodies," <i>J. Immunol.</i> , 127(2):505-509, 1981.
	C59	Johnson, "Review: Noncaspase proteases in apoptosis," <i>Leukemia</i> , 14:1695-1703, 2000.
	C60	Juhl <i>et al.</i> , "New approaches in gastric cancer research: I. Monoclonal antibodies in diagnosis and therapy," <i>Hepatogastroenterol.</i> 36:27-32, 1989.
	C61	Julius <i>et al.</i> , "Induction of resting B cells to DNA synthesis by soluble monoclonal anti-immunoglobulin," <i>Eur. J. Immunol.</i> , 14:753-757, 1984.
	C62	Kagawa <i>et al.</i> , "A binary adenoviral vector system for expressing high levels of the proapoptotic gene bax," <i>Gene Therapy</i> , 7:75-79, 2000.
	C63	Kagawa <i>et al.</i> , "Antitumor Effect of Adenovirus-mediated Bax Gene Transfer on p53-sensitive and p53-resistant Cancer Lines," <i>Cancer Research</i> , 60:1157-1161, 2000.
	C64	Kam <i>et al.</i> , "Review: Granzymes (lymphocyte serine proteases): characterization with natural and synthetic substrates and inhibitors," <i>Biochimica et Biophysica Acta</i> , 1477:307-323, 2000.
	C65	Kaneta <i>et al.</i> , "Effect of gelonin immunoconjugate with monoclonal antibody MSN-1 to endometrial adenocarcinoma on antigen-producing tumor cells in vivo," <i>Jpn J. Cancer Res.</i> , 89(5):583-588, 1998.

25527784.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:007US	Serial No. 10/074,596
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Michael Rosenblum et al.	
		Filing Date: February 12, 2002	Group: 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 3</i>	Other Art <i>See Page 4</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C66	Kimmel <i>et al.</i> , "In vitro drug sensitivity testing in human gliomas," <i>J. Neurosurg.</i> 66:161-171, 1987.
	C67	Kirkwood <i>et al.</i> , "Scintigraphic detection of metastatic melanoma using indium 111/DTPA conjugated anti-gp240 antibody (ZME-018)," <i>J. Clin. Oncol.</i> , 5:1247-1255, 1987.
	C68	Klein <i>et al.</i> , "Genomic organization and chromosomal assignment for a serine protease gene (CSPB) expressed by human cytotoxic lymphocytes," <i>Genomics</i> , 5(1):110-117, 1989.
	C69	Kovarik <i>et al.</i> , "Biochemical and histochemical characteristic of target antigen detected by monoclonal antibody HBCa-12 against a membrane component of human mammary carcinoma cell line," <i>Neoplasma</i> , 31(6):625-630, 1984.
	C70	Kufe <i>et al.</i> , "Differential reactivity of a novel monoclonal antibody (DF3) with human malignant vs. benign breast tumors," <i>Hybridoma</i> , 3(3):223-232, 1984.
	C71	Kung <i>et al.</i> , "A mouse IgM allotypic determinant (Igh-6.5) recognized by a monoclonal rat antibody," <i>J. Immunol.</i> 127:873-876, 1981.
	C72	Lambert <i>et al.</i> , "Immunotoxins containing single chain ribosome-inactivating proteins," in <i>Immunotoxins</i> , Frankel ed., pg 175-209, 1988.
	C73	Lambert <i>et al.</i> , "Purified immunotoxins that are reactive with human lymphoid cells. Monoclonal antibodies conjugated to the ribosome-inactivating proteins gelonin and the pokeweed antiviral proteins," <i>J. Biol. Chem.</i> , 260(22):12035-12041, 1985.
	C74	Lazar <i>et al.</i> , "Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities," <i>Mol. Cell. Biol.</i> , 8:1247-1252, 1988.
	C75	Leibovitz <i>et al.</i> , "A hypo-osmotic medium to disaggregate tumor cell clumps into viable and clonogenic single cells for the human tumor stem cell clonogenic assay," <i>Int. J. Cell Cloning</i> , 1:478-485, 1983.
	C76	Lewis and Crowe, "Generation of humanized monoclonal antibodies by 'best' fit framework selection and recombinant polymerase chain reaction," <i>Year Immunol.</i> , 7:110-118, 1993.
	C77	Lin <i>et al.</i> , "Chromosomal localization of two human serine protease genes to region 14q11.2---q12 by in situ hybridization," <i>Cytogenet Cell Genet.</i> , 53(2-3):169-171, 1990.
	C78	Lubin <i>et al.</i> , "Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis," <i>J. Biol. Chem.</i> , 272(48):30191-30195, 1997.

25527784.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. CLFR:007US	Serial No. 10/074,596
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)	Applicant Michael Rosenblum et al.	
	Filing Date: February 12, 2002	Group: 1614
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 3	Other Art See Page 4

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C79	Miescher-Granger <i>et al.</i> , "Biological activities of human recombinant interferon alpha/beta targeted by anti-Epstein-Barr virus monoclonal antibodies," <i>FEBS Lett.</i> , 179:29-33, 1985.
	C80	Mihich, "Future perspectives for biological response modifiers: a viewpoint," <i>Sem Oncol.</i> , 13:234-254, 1986.
	C81	Montanaro <i>et al.</i> , "A metalloproteinase associated with gelonin, a ribosome inactivating protein," <i>Ital. J. Biochem.</i> , pg 1-10, 1984.
	C82	Moola <i>et al.</i> , "Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes," <i>Biochem J.</i> , 302( Pt 3):921-7, 1994.
	C83	Motyka <i>et al.</i> , "Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis," <i>Cell</i> , 103(3):491-500, 2000.
	C84	Mujoo <i>et al.</i> , "Pharmacology and therapeutic studies with ZME-gelonin immunotoxin," <i>Proc. Am Assoc. Cancer Res</i> , 32:266, #1580, 1991.
	C85	Murray <i>et al.</i> , "Clinical parameters related to optimal tumor localization of indium-111-labeled mouse antimelanoma monoclonal antibody ZME-018" <i>J. Nuclear Med.</i> , 28:25-33, 1987.
	C86	Murray <i>et al.</i> , "Differential in vitro effects of alpha recombinant interferon and gamma recombinant interferon on the expression of melanoma-associated antigens and 240 Kd on melanoma cell line Ts294," <i>AACR</i> , 27:313, 1986.
	C87	Murray <i>et al.</i> , "Differential in vitro effects of recombinant alpha-interferon and recombinant gamma-interferon alone or in combination on the expression of melanoma-associated surface antigens," <i>J. Biol. Response Modifiers</i> , 7:152-161, 1988.
	C88	Neville <i>et al.</i> , "Monoclonal antibody-ricin or ricin A chain hybrids: kinetic analysis of cell killing for tumor therapy," <i>Immunol. Rev.</i> , 62:75-91, 1982.
	C89	Nolan <i>et al.</i> , "Cloning and expression of a gene encoding gelonin, a ribosome-inactivating protein from <i>Gelonium multiflorum</i> ," <i>Gene</i> , 134:223-227, 1993.
	C90	Nuti <i>et al.</i> , "A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations," <i>Int. J. Cancer</i> , 29(5):539-546, 1982.
	C91	Ozawa <i>et al.</i> , "Selective killing of squamous carcinoma cells by an immunotoxin that recognizes the EGF receptor," <i>Int. J. Cancer</i> , 43:152-157, 1989.

25527784.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:007US	Serial No. 10/074,596
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Michael Rosenblum et al.	
		Filing Date: February 12, 2002	Group: 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 3</i>	Other Art <i>See Page 4</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C92	Pagliaro <i>et al.</i> , "Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity," <i>Clin. Cancer Res.</i> , 4(8):1971-1976, 1998.
	C93	Pai and Pastan "Immunotoxin therapy for cancer," <i>JAMA</i> , 269:78-81, 1993.
	C94	Pastan <i>et al.</i> , "Recombinant toxins for cancer treatment," <i>Science</i> , 254:1173-1177, 1991.
	C95	Pearson <i>et al.</i> , "Enhanced therapeutic efficacy against an ovarian tumor xenograft of immunotoxins used in conjunction with recombinant alpha-interferon," <i>Cancer Res.</i> 50:6379-6388, 1990.
	C96	Pelham <i>et al.</i> , "Interferon-alpha conjugation to human osteogenic sarcoma monoclonal antibody 791T/36," <i>Cancer Immunol. Immunother.</i> , 15:210-216, 1983.
	C97	Ramakrishnan and Houston, "Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors: pokeweed antiviral protein or ricin A chain," <i>Cancer Res.</i> , 44(4):1398-404, 1984.
	C98	Raso <i>et al.</i> , "Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen." <i>Cancer Res.</i> , 42:457-464, 1982.
	C99	Reimann <i>et al.</i> , "In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. IV. Cytotoxic effect of an anti-T11-gelonin immunotoxin," <i>J. Clin. Invest.</i> , 82:129-138, 1988.
	C100	Rissoan <i>et al.</i> , "Subtractive hybridization reveals the expression of immunoglobulinlike transcript 7, Eph-B1, granzyme B and 3 novel transcripts in human plasmacytoid dendritic cells," <i>Blood</i> , 100(9):3295-3303, 2002.
	C101	Rosenblum <i>et al.</i> , "A gelonin-containing immunotoxin directed against human breast carcinoma," <i>Mol. Biother.</i> 4:122-129, 1992.
	C102	Rosenblum <i>et al.</i> , "Antibody-mediated delivery of tumor necrosis factor (TNF- $\alpha$ )," <i>Proc. Am Cancer Res.</i> , 30:410, #1522, 1987.
	C103	Rosenblum <i>et al.</i> , "Antibody-mediated delivery of tumor necrosis factor (TNF-alpha): improvement of cytotoxicity and reduction of cellular resistance," <i>Cancer Commun.</i> 3:21-27, 1991.

25527784.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:007US	Serial No. 10/074,596
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Michael Rosenblum et al.	
		Filing Date: February 12, 2002	Group: 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 3</i>	Other Art <i>See Page 4</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C104	Rosenblum <i>et al.</i> , "Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2',5'-oligoadenylate synthetase and protein kinase activity," <i>Interferon Res.</i> , 10:141-151, 1990.
	C105	Rosenblum <i>et al.</i> , "Monoclonal Antibodies for delivery of cytokines," <i>Cancer Bull.</i> , 46(1):34-39, 1994.
	C106	Rosenblum <i>et al.</i> , "An antimelanoma immunotoxin composed of antibody AMI-018 and the plant toxin gelonin," , " <i>Proc. Am. Assoc. Cancer Res. Annu. Meet.</i> , 29:427, #1700, 1988 (Abstract)
	C107	Rosenblum <i>et al.</i> , "Tumor necrosis factor a: multifaceted peptide hormone," <i>Critical Reviews in Immunology</i> , pgs 21-44, 1989
	C108	Ross <i>et al.</i> , "Increased toxicity of diphtheria toxin for human lymphoblastoid cells following covalent linkage to anti-(human lymphocyte) globulin or its F(ab') <sub>2</sub> fragment," <i>Eur. J. Biochem.</i> 104:381-390, 1980.
	C109	Roy <i>et al.</i> , "Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells," <i>Blood</i> , 77:2404-2412, 1991.
	C110	Salmon and Liu "Effects of granulocyte-macrophage colony-stimulating factor on in vitro growth of human solid tumors," <i>J. Clin. Oncol.</i> , 7:1346-1350, 1989.
	C111	Salmon <i>et al.</i> , "Evaluation of an automated image analysis system for counting human tumor colonies," <i>Internat. J. Cell Cloning</i> , 2:142-160, 1984.
	C112	Salmon <i>et al.</i> , "Quantitation of differential sensativity of human-tumor stem cells to anticancer drugs," <i>New Eng. J. Med.</i> , 298:1321-1327, 1978.
	C113	Schienberg <i>et al.</i> , "Monoclonal Antibody M195:A diagnostic marker for acute myelogenous leukemia," <i>Leukemia</i> , 3(6):440-445, 1989.
	C114	Scholz <i>et al.</i> , "Correlation of drug response in patients and in the clonogenic assay with solid human tumour xenografts," <i>Eur. J. Cancer</i> , 26(8):901-905, 1990.
	C115	Schulz <i>et al.</i> , "Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo," <i>Proc. Natl. Acad. Sci. USA</i> , 80:5407-5411, 1983.

25527784.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:007US	Serial No. 10/074,596
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Michael Rosenblum et al.	
		Filing Date: February 12, 2002	Group: 1614
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 3	Other Art See Page 4	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C116	Scott <i>et al.</i> , "An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors," <i>J. Natl. Cancer Inst.</i> , 79:1163-1172, 1987.
	C117	Shoemaker <i>et al.</i> , "Application of a human tumor colony-forming assay to new drug screening," <i>Cancer Res.</i> , 45:2145-2153, 1985.
	C118	Singh <i>et al.</i> , "Hormonotoxins. Preparation and characterization of ovine luteinizing hormone-gelonin conjugate," <i>J. Biol. Chem.</i> , 264(6):3089-3095, 1989.
	C119	Sivam <i>et al.</i> , "Immunotoxins to a human melanoma-associated antigen: comparison of gelonin with ricin and other A chain conjugates," <i>Cancer Res.</i> , 47:3169-3173, 1987
	C120	Smyth <i>et al.</i> , "Granzymes: exogenous proteinases that induce target cell apoptosis," <i>Immunology Today</i> , 16(4):202 - 206, 1995.
	C121	Soule <i>et al.</i> , "Membrane 126-kilodalton phosphoglycoprotein associated with human carcinomas identified by a hybridoma antibody to mammary carcinoma cells," <i>Proc. Natl. Acad. Sci. USA</i> , 80:1332-1336, 1983.
	C122	Spitler <i>et al.</i> , "Immunotoxin therapy of malignant melanoma," <i>Med Oncol Tumor Pharmacother.</i> , 3:147-152, 1986.
	C123	Spitler <i>et al.</i> , "Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin," <i>Cancer Res.</i> , 47:1717-1723, 1987.
	C124	Spitler <i>et al.</i> , "Therapy of metastatic malignant melanoma using XomaZyme Mel, a murine monoclonal anti-melanoma ricin A chain immunotoxin," <i>Nuc. Med. And Biol.s.</i> , 16:625-627, 1989.
	C125	Tai <i>et al.</i> , "In Vivo Cytotoxicity of Ovarian Cancer Cells through Tumor-selective Expression of the BAX Gene," <i>Cancer Res.</i> , 59:2121-2126, 1999.
	C126	Tao <i>et al.</i> , "Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region," <i>J. Immunol.</i> , 143:2595-2601, 1989.
	C127	Tedder <i>et al.</i> , "Epstein Barr virus binding induces internalization of the C3d receptor: a novel immunotoxin delivery system," <i>J. Immunol.</i> 137(4):1387-1391, 1986.

25527784.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:007US	Serial No. 10/074,596
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Michael Rosenblum et al.	
		Filing Date: February 12, 2002	Group: 1614
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 3	Other Art See Page 4	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C128	Thorpe <i>et al.</i> , "An immunotoxin composed of monoclonal anti-thy 1.1 antibody and a ribosome-inactivating protein from saponaria oddicalis: potent antitumor effects in vitro and in vivo," <i>J. Natl. Cancer Inst.</i> , 75(1):151-159, 1985.
	C129	Thorpe <i>et al.</i> , "Cytotoxicity acquired by conjugation of an anti-Thy1.1 monoclonal antibody and the ribosome-inactivating protein, gelonin," <i>Eur. J. Biochem.</i> , 116:447-454, 1981.
	C130	Thorpe <i>et al.</i> , "Monoclonal antibodies: clinical and regulatory issues," <i>Trends Biotechnol.</i> 11:40-42, 1993.
	C131	Till <i>et al.</i> , "An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins," <i>Cancer Res.</i> 48:1119-1123, 1988.
	C132	Trowbridge <i>et al.</i> , "Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumour cells," <i>Nature</i> , 294:171-173, 1981.
	C133	Vitetta <i>et al.</i> , "Neoplastic B cells as targets for antibody-ricin A chain immunotoxins," <i>ibid.</i> , 62:15-183, 1982.
	C134	Vitetta <i>et al.</i> , "Redesigning nature's poisons to create anti-tumor reagents," <i>Science</i> , 238:1098-1104, 1987.
	C135	Vogel <i>et al.</i> , "In vivo studies with covalent conjugates of cobra venom factor and monoclonal antibodies to human tumors," <i>Hematology and Blood Transfusion</i> , 29:514-517, 1989.
	C136	Von Hoff, "Human tumor cloning assays: applications in clinical oncology and new antineoplastic agent development," <i>Cancer and Metastasis Reviews</i> , 7:357-371, 1988.
	C137	Waldenamn, "Multichain interleukin-2 receptor: a target for immunotherapy in lymphoma," <i>J. Natl. Cancer Inst.</i> 81:914-923, 1989.
	C138	Waldmann <i>et al.</i> , "Monoclonal antibodies in diagnosis and therapy," <i>Science</i> , 252:1657-1662, 1991.
	C139	White <i>et al.</i> , "Two monoclonal antibodies selective for human mammary carcinoma" <i>Cancer Res.</i> , 45:1337-1343, 1985.
	C140	Wilson <i>et al.</i> , "Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies," <i>Int. J. Cancer</i> , 28:293-300, 1981.

25527784.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:007US	Serial No. 10/074,596
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Michael Rosenblum et al.	
		Filing Date: February 12, 2002	Group: 1614
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 3	Other Art See Page 4	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C141	Yeung <i>et al.</i> , "Trichosanthin, $\alpha$ -momorcharin and $\beta$ -momorcharin: identity of aborifacient and ribosome-inactivating proteins," <i>Int. J. Pept. Protein Res.</i> , 31(3):265-8, 1988.
	C142	Yokota <i>et al.</i> , "Synergistic potentiation of in vivo antitumor activity of anti-human T-leukemia immunotoxins by recombinant alpha-interferon and daunorubicin," <i>Cancer Res.</i> , 50:32-37, 1990.
	C143	Young, "Cell-Mediated Killing: A common Mechanism?" <i>Cell</i> , 46:641-642, 1986.
	C144	Yung <i>et al.</i> , "In vitro chemosensitivity testing and its clinical application in human gliomas," <i>Neurosurg. Rev.</i> , 12:197-203, 1989.
	C145	Zuckerman <i>et al.</i> , "Preparation and biological activity of recombinant leukocyte interferon A [rIFN alpha A] conjugated to an antimelanoma murine monoclonal antibody [ZME-018]," <i>Proc. Amer. Assoc. Cancer Res.</i> , 28:384, 1987.
	C146	Aboud-Pirak <i>et al.</i> , "Cytotoxic activity of daunorubicin or vindesine conjugated to a monoclonal antibody on cultured MCF-7 breast carcinoma cells," <i>Biochem. Pharmacol.</i> , 38:641-648, 1989.
	C147	Adams <i>et al.</i> , "The Bcl-2 Protein Family: Arbiters of Cell Survival," <i>Science</i> , 281:1322-1326, 1998.
	C148	Aggarwal and Kohr, "Human tumor necrosis factor," <i>Methods in Enzymology</i> , 116:448-456, 1986.
	C149	Alkan <i>et al.</i> , "Antiviral and antiproliferative effects of interferons delivered via monoclonal antibodies," <i>J. Interferon Res.</i> , 4(3):355-363, 1984.
	C150	Alley <i>et al.</i> , "Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay," <i>Cancer Res.</i> , 48:589-601, 1988.
	C151	Aqeilan <i>et al.</i> , "Interleukin 2-Bax: a novel prototype of human chimeric proteins for targeted therapy," <i>FEBS Letters</i> , 457:271-276, 1999.
	C152	Arnon <i>et al.</i> , "Monoclonal antibodies for immunotargeting of drugs in cancer therapy," <i>Monoclonal Antibodies and Cancer Therapy</i> , Alan R. Liss, Inc. pp 243-256, 1985.
	C153	Atkinson <i>et al.</i> , "Conjugation of folate via gelonin carbohydrate residues retains ribosomal-activating properties of the toxin and permits targeting to folate receptor positive cells," <i>Biochem Molec. Biol.</i> , 276(30):27930-27935, 2001.

25527784.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)		Atty. Docket No. CLFR:007US	Serial No. 10/074,596
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Michael Rosenblum et al.	
		Filing Date: February 12, 2002	Group: 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 3</i>	Other Art <i>See Page 4</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C154	Barbieri and Stirpe, "Ribosome-inactivating proteins from plants: Properties and possible uses," <i>Cancer Surveys</i> , 1(3):489-520.
	C155	Batra <i>et al.</i> , "Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin," <i>Proc. Natl. Acad. Sci.</i> , 86:8545-8549, 1989.
	C156	Batra <i>et al.</i> , "Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv)," <i>Mol. Cell. Biol.</i> 11:2200-2205, 1991.
	C157	Bendig, "Humanization of rodent monoclonal antibodies by CDR grafting," <i>METHODS: A Companion to Methods in Enzymology</i> , 8:83-93, 1995.
	C158	Bjorn <i>et al.</i> , "Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins," <i>Cancer Res.</i> , 45:1214-1221, 1985.
	C159	Blair <i>et al.</i> , "Linkage of cytotoxic agents to immunoglobulins," <i>J. Immunol. Methods</i> , 59:129-143, 1983.
	C160	Blakey <i>et al.</i> , "Antibody toxin conjugates: a perspective," <i>Monoclonal Antibody Therapy</i> . Waldmann (ed). 45:50-90, 1988.
	C161	Blink <i>et al.</i> , "Curtin Conference: Perforin-dependent nuclear targeting of granzymes: A central role in the nuclear events of granule-exocytosis-mediated apoptosis?," <i>Immunology and Cell Biology</i> , 77:206-215, 1999.
	C162	Bolognesi <i>et al.</i> , "In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins," <i>Br. J. Haematol.</i> , 110(2):351-361, 2000.
	C163	Bradford <i>et al.</i> , "A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding," <i>Analy. Biochem.</i> , 72:248-252, 1976.
	C164	Brunet <i>et al.</i> , "The inducible cytotoxic T-lymphocyte-associated gene transcript CTLA-1 sequence and gene localization to mouse chromosome 14," <i>Nature</i> , 322(6076):268-271, 1986.
	C165	Bumol <i>et al.</i> , "Biosynthetic studies of proteoglycans in human melanoma cells with a monoclonal antibody to a core glycoprotein of chondroitin sulfate proteoglycans," <i>J. Biol. Chem.</i> , 259:12733-12741, 1984.

25527784.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:007US	Serial No. 10/074,596
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Michael Rosenblum et al.	
		Filing Date: February 12, 2002	Group: 1614
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 3	Other Art See Page 4	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C166	Chan <i>et al.</i> , "Comparison of gallium-67 versus indium-111 monoclonal antibody (96.5, ZME-018) in detection of human melanoma in athymic mice," <i>J. Nucl. Med.</i> , 28:1441-1446, 1987.
	C167	Chaudhary <i>et al.</i> , "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin," <i>Nature</i> , 339:394-397, 1989.
	C168	Collen <i>et al.</i> , "Recombinant staphylokinase variants with altered immunoreactivity," <i>Circulation</i> , 94:197-206, 1996.
	C169	Cotton <i>et al.</i> , "Somatic mutation and the origin of the antibody diversity. Clonal variability of the immunoglobulin produced by MOPC 21 cells in culture," <i>Eur. J. Immunol.</i> , 3:135-140, 1973.
	C170	Crosby <i>et al.</i> , "A complex of serine protease gene expressed preferentially in cytotoxic T-lymphocytes is closely linked to the T-cell receptor alpha- and delta-chain genes on mouse chromosome 14," <i>Genomics</i> , 6(2):252-259, 1990.
	C171	Dahl <i>et al.</i> , "Isolation of a cDNA clone encoding a novel form of granzyme B from human NK cells and mapping to chromosome 14," <i>Hum. Genet.</i> , 84(5):465-470, 1990.
	C172	DeLand <i>et al.</i> , "A perspective of monoclonal antibodies: past, present, and future," <i>Seminars in Nuc. Med.</i> , 19(3):158-165.
	C173	Dermer, "Another anniversary for the war on cancer," <i>Bio/technology</i> , 12:320, 1994.
	C174	Dillman, "Monoclonal antibodies for treating cancer," <i>Ann. Intern. Med.</i> , 111:592-603, 1989.
	C175	Dumontet, "[Immunotherapy and cancer: the role of monoclonal antibodies]," <i>J. Chir. (Paris)</i> , 126:682-686, 1989.
	C176	Engert <i>et al.</i> , "Resistance of myeloid leukaemia cell lines to ricin A-chain immunotoxins," <i>Leuk. Res.</i> , 15:1079-1086, 1991.
	C177	Falasca <i>et al.</i> , "Properties of the ribosome-inactivating proteins gelonin, Momordica charantia inhibitor, and dianthins," <i>Biochem. J.</i> , 207:505-509, 1982.
	C178	Fiers <i>et al.</i> , "Tumor necrosis factor: a potential anti tumor agent," <i>J. Interferon Res.</i> , 7:627-634, 1987.
	C179	Flannery <i>et al.</i> , "Immunomodulation: NK cells activated by interferon-conjugated monoclonal antibody against human osteosarcoma" <i>Eur. J. Cancer Clin. Oncol.</i> , 20:791-798, 1984.

25527784.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:007US	Serial No. 10/074,596
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Michael Rosenblum et al.	
		Filing Date: February 12, 2002	Group: 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 3</i>	Other Art <i>See Page 4</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C180	Frankel <i>et al.</i> , "Prospects for immunotoxin therapy in cancer," <i>Ann. Rev. Med.</i> , 37:125-142, 1986.
	C181	Freshney, "Culture of animal cells, a manual of basic technique," Alan R. Liss, Inc, 1983.
	C182	Friedman <i>et al.</i> , "BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells," <i>Cancer Res.</i> , 53:334-339, 1993.
	C183	Frontiera <i>et al.</i> , "Sequential use of indium-111 labeled monoclonal antibodies 96.5 and ZME-018 does not increase detection sensitivity for metastatic melanoma," <i>Clin. Nucl. Med.</i> , 14:357-366, 1989.
	C184	Gallego <i>et al.</i> , "Preparation of four daunomycin-monoclonal antibody 791T/36 conjugates with anti-tumour activity," <i>Int. J. Cancer</i> , 33:737-744, 1984.

25527784.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.